Mirum Pharmaceuticals (MIRM) had its price target raised by TD Cowen from $117.00 to $125.00. They now have a "buy" rating on the stock.
Mirum Pharmaceuticals (MIRM) had its "buy" rating reaffirmed by HC Wainwright. They now have a $130.00 price target on the stock.
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases [Yahoo! Finance]
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)